Edward Lee Carter: What If Better Stroke Prevention Didn’t Require More Bleeding?
Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post on LinkedIn:
”What if better stroke prevention didn’t require more bleeding?
For decades, antithrombotic therapy has relied on a familiar tradeoff:
- Prevent more thrombosis
- Accept more bleeding
The Phase III OCEANIC-STROKE trial suggests that assumption may deserve another look.
Investigators randomized 12,327 patients with a recent non-cardioembolic ischemic stroke or high-risk TIA to receive:
- Asundexian 50 mg daily plus standard antiplatelet therapy
- Placebo plus standard antiplatelet therapy
The results were notable:
- 26percent relative reduction in recurrent ischemic stroke
- 20percent relative reduction in major cardiovascular events
- No statistically significant increase in ISTH major bleeding
Event rates:
- Recurrent ischemic stroke: 6.2percent vs 8.4percent
- Major cardiovascular events: 7.4percent vs 9.2percent
- ISTH major bleeding: 1.9percent vs 1.7percent
What makes this especially interesting is the target.
Asundexian inhibits Factor XIa, a component of coagulation believed to play a larger role in pathologic thrombosis than in normal hemostasis.
The goal is straightforward:
- Reduce thrombosis
- Preserve hemostatic function
- Improve outcomes without substantially increasing bleeding risk
Important caveats:
- These findings apply to secondary prevention after non-cardioembolic stroke or high-risk TIA.
- They should not be extrapolated to atrial fibrillation, venous thromboembolism, mechanical valves, or antiphospholipid syndrome.
- Additional studies are needed before Factor XI inhibition can be considered a new standard of care.
Still, OCEANIC-STROKE may represent one of the most important developments in thrombosis research since the arrival of DOACs.
Not because it proves we have solved the bleeding problem.
But because it suggests we may finally be asking the right question:
Can we separate thrombosis prevention from bleeding risk more effectively than we ever have before?
If that proves possible, the implications will extend far beyond stroke prevention.
What are your thoughts on Factor XI inhibition? A genuine breakthrough – or promising but still unproven?”
Stay updated with Hemostasis Today.
-
Jun 10, 2026, 04:50Antoine Francis: Plasma as the Internet of the Human Body
-
Jun 10, 2026, 04:45Judith Catella: New Evidence on Distal Deep Vein Thrombosis from the RIETE Registry
-
Jun 10, 2026, 04:20Ravindra Prasad Thokala: When T Cells Heal and Harm in the Same Transplant Unit
-
Jun 10, 2026, 04:15Jukka Partanen: How Blood Donation Selection Shapes the Human Genome Landscape
-
Jun 10, 2026, 04:02Heghine Khachatryan: What Should We Test From a Hematologic Perspective in Young Cryptogenic Stroke?
-
Jun 9, 2026, 17:55Can We Prevent Postpartum Blood Clots without Putting Most Women on Heparin? – RPTH Journal
-
Jun 9, 2026, 17:54Lucky Oseghale Oloboh: Health Is Power, Health Is Personal, and Health Is Our First Responsibility in Life’s Journey on Mother Earth
-
Jun 9, 2026, 17:53Ajay Samkaria: How ABO Subgroups Directly Impact Transfusion Safety
-
Jun 9, 2026, 17:51Alejandro González Veliz: Most Reported Aspirin Allergies Are Not True Hypersensitivity